Dai ichi Life Insurance Company Ltd Purchases 33,000 Shares of Centene Co. (NYSE:CNC)

Dai ichi Life Insurance Company Ltd lifted its position in Centene Co. (NYSE:CNC) by 820.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,020 shares of the company’s stock after acquiring an additional 33,000 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Centene were worth $2,787,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the company. Park Place Capital Corp increased its position in Centene by 1,190.0% during the 3rd quarter. Park Place Capital Corp now owns 387 shares of the company’s stock valued at $29,000 after purchasing an additional 357 shares during the period. WR Wealth Planners LLC raised its holdings in shares of Centene by 41.4% in the 2nd quarter. WR Wealth Planners LLC now owns 468 shares of the company’s stock valued at $31,000 after purchasing an additional 137 shares in the last quarter. Chris Bulman Inc bought a new stake in shares of Centene in the 2nd quarter valued at about $33,000. Riverview Trust Co raised its holdings in shares of Centene by 154.6% in the 2nd quarter. Riverview Trust Co now owns 527 shares of the company’s stock valued at $35,000 after purchasing an additional 320 shares in the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Centene in the 2nd quarter valued at about $36,000. Institutional investors own 93.63% of the company’s stock.

Insider Buying and Selling

In related news, CEO Sarah London bought 4,117 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were purchased at an average cost of $60.80 per share, with a total value of $250,313.60. Following the transaction, the chief executive officer now directly owns 667,229 shares of the company’s stock, valued at approximately $40,567,523.20. This represents a 0.62 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Andrew Lynn Asher purchased 17,200 shares of Centene stock in a transaction that occurred on Wednesday, November 13th. The stock was bought at an average cost of $58.14 per share, with a total value of $1,000,008.00. Following the completion of the transaction, the chief financial officer now owns 486,847 shares of the company’s stock, valued at $28,305,284.58. The trade was a 3.66 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.29% of the company’s stock.

Centene Trading Down 0.1 %

NYSE CNC opened at $59.92 on Thursday. Centene Co. has a 52 week low of $57.20 and a 52 week high of $81.42. The firm has a 50 day moving average of $65.74 and a two-hundred day moving average of $70.12. The stock has a market capitalization of $30.25 billion, a PE ratio of 10.40, a price-to-earnings-growth ratio of 0.84 and a beta of 0.49. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.64.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CNC. Wells Fargo & Company reduced their price target on shares of Centene from $91.00 to $90.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Robert W. Baird reduced their price objective on shares of Centene from $83.00 to $66.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Cantor Fitzgerald reiterated an “overweight” rating and set a $90.00 price objective on shares of Centene in a research note on Tuesday, October 1st. Barclays reduced their price objective on shares of Centene from $97.00 to $91.00 and set an “overweight” rating for the company in a research note on Tuesday, October 29th. Finally, TD Cowen boosted their price objective on shares of Centene from $80.00 to $89.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Centene presently has an average rating of “Moderate Buy” and a consensus price target of $83.92.

Centene Company Profile

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children’s health insurance program, foster care, medicare-medicaid plans, long-term services and support.